Alphabet Inc. GOOGL

Latest Deep Dive · Written · AI research note

Verdict

Deep Dive

Rating

BUY

Confidence

70%

Target price

$420.00

Upside

▲ 22.0%

Horizon

medium

Alphabet trades at a genuine discount to mega-cap peers on a clean ~21x forward P/E, with 24.6% forward revenue growth, a 34% operating margin, and 49% ROE, while the market prices in AI search disruption and antitrust remedies rather than deteriorating fundamentals. The base case fair value of $410-$425 implies roughly 20% upside, consistent with the $430 consensus, with a benign antitrust outcome the largest re-rating catalyst. Risks are binary and material—particularly an adverse ad tech divestiture that could push the stock toward $300—so conviction is solid but not maximal.

Executive Summary

•Alphabet trades at ~21x clean NTM P/E (EQRV BF P/E 21.1x) versus MSFT at 29.7x and META at 26.6x TTM P/E, a ~25 to 30% discount that prices in AI search disruption and antitrust remedies rather than current fundamentals.
•The headline 54.8% TTM net margin is a data artifact: Q4 net income of $112.11b on $119.80b revenue reflects large one time investment gains, so normalised net income is closer to a ~$140b annual run rate (~31% margin).
•Google Cloud scale up plus external TPU monetisation are the swing value drivers, but the raised 2026 capex guide of $195 to $205b creates a depreciation drag that compresses near term free cash flow even as revenue compounds.
•Antitrust is the binary risk: search default distribution remedies and an ad tech divestiture could each remove material revenue, while the consensus PT of $430 implies ~25% upside if remedies land benignly.

Financial Snapshot

•Revenue (TTM): $445.87b
•Revenue growth (forward NTM): +24.6%
•Gross margin: 60.9%
•Operating margin: 34.0%
•Net margin (TTM): 54.8% (inflated by one time gains)
•Normalised net margin: ~31% (est)
•ROE: 48.7%
•Debt/Equity: 18.9%
•Market cap: $4,105.66b
•Current price: $344.18
•52 week range: $244.15 to $408.61
•Q4 revenue: $119.80b, net income $112.11b (one time gains)
•Q3 revenue: $109.90b, net income $62.58b
•Q2 revenue: $113.83b, net income $34.45b
•Q1 revenue: $102.35b, net income $34.98b

Forward Outlook

•NTM revenue estimate: $498.79b (+24.6% YoY)
•FY+2 revenue estimate: $621.65b
•NTM EPS consensus: $20.59 headline, but the revision trend tracks $16.34 on a cleaner basis
•FY+2 EPS estimate: $15.30, flagged as inconsistent with the $20.59 headline
•NTM EPS revisions: -1.8% over 1 month, a mild negative drift
•2026 capex guide: $195 to $205b, up sharply year over year
•Operating margin expected to hold near 34% despite the capex step up
•Depreciation drag to build through 2026 as prior capex converts to expense

Valuation Analysis

•NTM P/E (headline): 16.71x on $20.59 EPS
•NTM P/E (clean): ~21.1x on $16.34 EPS (EQRV BF P/E), versus 2y average 22.0x
•NTM P/S: 8.44x on $498.79b forward revenue
•NTM EV/EBIT: 7.8x (EQRV), flagged as distorted by one time gains inflating the denominator
•NTM EV/EBITDA: 6.8x (EQRV), same distortion caveat
•TTM P/E: ~16.8x on reported earnings, ~29x on normalised earnings
•EQRV BF EV/Rev 3.2x versus 2y average 5.0x (-36%, -2.1 SD)
•EQRV LF P/BV 6.8x versus 2y average 5.0x (+37%, +1.3 SD)
•MSFT: ~29.7x TTM P/E, $3,961.7b cap, cloud and AI leadership
•META: ~26.6x TTM P/E, $1,797.1b cap, digital ads and AI infra exposure
•AMZN: ~21.1x TTM P/E, $2,830.9b cap, AWS and retail diversification
•Consensus price target: $430.3 (median $425, range $350 to $485)
•Fair value (base case): $410 to $425, ~20% upside
•Bull case: $485 (antitrust clarity plus TPU external sales)
•Bear case: $300 (adverse ad tech divestiture plus AI search monetisation decay)

Key Risks & Catalysts

Risks

•Search default remedy could force changes to distribution deals, pressuring traffic acquisition costs and query share
•Ad tech divestiture of the ad exchange could remove a high margin revenue layer
•Publisher damages exceeding $3.2b add to legal overhang
•AI Overviews and AI Mode may lower paid click monetisation per query as answers replace links
•$195 to $205b capex drives depreciation and free cash flow compression into 2026
•NTM EPS revisions are negative (-1.8% over 1 month)
•Gemini faces intense competition from OpenAI and Anthropic on model quality and enterprise adoption
•13F holders fell 4,962 QoQ and a put/call ratio of 1.80 signals cautious positioning

Catalysts

•External TPU sales (Meta reportedly in talks) would open a high growth silicon revenue stream
•Google Cloud backlog conversion sustaining ~30% growth
•Gemini monetisation via Google One and Workspace subscriptions
•Waymo and Other Bets optionality
•Antitrust remedy clarity removing the valuation overhang
•Continued buyback support at ~21x forward earnings

Investment Thesis

Alphabet is a high quality compounder trading at a genuine discount to mega cap peers, but the discount is narrower than headline screens suggest. The 16.71x NTM P/E rests on a $20.59 EPS figure that appears inflated by one time investment gains, while the cleaner forward multiple is ~21x. Even on that basis Alphabet sits below MSFT and META and roughly in line with AMZN, against 24.6% forward revenue growth and a 34% operating margin. The market is paying for AI search disruption and antitrust risk, not for a deteriorating core.

The two variables that decide the outcome are Cloud and capital intensity. Google Cloud scale up, a large backlog, and external TPU monetisation would lift both growth and margin mix, since owned silicon carries better economics than purchased GPUs. Against that, the $195 to $205b capex guide converts to a rising depreciation charge that will suppress free cash flow through 2026. The question is whether revenue and margin expansion outrun the depreciation drag, and the resilient 34% operating margin suggests it can.

I rate Alphabet a Buy with a base case fair value of $410 to $425, roughly 20% upside and consistent with the $430 consensus. The clean 21x forward multiple offers an attractive entry for a franchise with 49% ROE and a fortress balance sheet. The key monitorables are the antitrust remedy rulings and the pace of Cloud and TPU revenue disclosure; a benign remedy outcome is the single largest re rating catalyst, while an adverse ad tech divestiture is the main downside scenario toward $300.

Written by AI from financials, consensus, filings and recent news. General information only, not personal financial advice. Consider your own circumstances before acting.

The Equity Analyst

Run your own analysis free

The Equity Analyst writes a note like this on any US, ASX or global stock in a few minutes: the thesis, valuation, catalysts, risks and a Buy, Hold or Sell call with a 12-month target. It comes with the daily market wrap, live markets, earnings and charts. Sign in and you get 7 days of full access free, no card needed.

Download on the App Store

See the latest research on other stocks